Ex vivo expansion of megakaryocyte precursor cells in autologous stem cell transplantation for relapsed malignant lymphoma
| Autor: | Marie-Laure Bonnet, Françoise Farace, Greissenger N, Vantelon Jm, Martine Guillier, Assari S, Marracho Mc, Catherine Boccaccio, Fariba Nemati, J. H. Bourhis, Jean Michon, Ali G. Turhan, A. L. Bennaceur, Didier Decaudin |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Platelet Membrane Glycoprotein IIb
Pathology medicine.medical_specialty Lymphoma Cell Culture Techniques Antigens CD34 Platelet Transfusion Transplantation Autologous Autologous stem-cell transplantation Antineoplastic Combined Chemotherapy Protocols medicine Autologous transplantation Humans Progenitor cell Cyclophosphamide Melphalan Cells Cultured Erythroid Precursor Cells Salvage Therapy Transplantation Peripheral Blood Stem Cell Transplantation business.industry Cytarabine Integrin beta3 Hematology medicine.disease Carmustine Thrombocytopenia Graft-versus-host disease Platelet transfusion Treatment Outcome Thrombopoietin Cancer research Stem cell business Megakaryocytes Ex vivo |
| Zdroj: | Bone marrow transplantation. 34(12) |
| ISSN: | 0268-3369 |
| Popis: | To evaluate the impact of ex vivo expanded megakaryocyte (MK) progenitors on high-dose chemotherapy-induced thrombocytopenia, we conducted a phase II study in 10 patients with relapsed lymphoma. Two fractions of peripheral blood progenitor cells (PBPC) were cryopreserved, one with enough cells for at least 2 x 10(6) CD34+ cells/kg and a second obtained after CD34+ selection. Ten days before autologous stem cell transplantation, the CD34+ fraction was cultured with MGDF+SCF for 10 days. After BEAM (BCNU, cyclophosphamide, cytarabine, and melphalan) chemotherapy, patients were reinfused with standard PBPC and ex vivo expanded cells. No toxicity was observed after reinfusion. The mean fold expansion was 9.27 for nucleated cells, 2 for CD34+ cells, 676 for CD41+ cells, and 627 for CD61+ cells. The median date of platelet transfusion independence was day 8 (range: 7-12). All patients received at least one platelet transfusion. In conclusion, ex vivo expansion of MK progenitors was feasible and safe, but this procedure did not prevent BEAM-induced thrombocytopenia. Future studies will determine if expansion of higher numbers of CD34+ cells towards the MK-differentiation pathway will translate into a functional effect in terms of shortening of BEAM-induced thrombocytopenia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|